8月17日 - ** 抗癌药物开发商 Faeth Therapeutics（FTH.O）的股价在盘前交易中上涨 2%，至 33 美元
** 该公司表示，美国食品药品监督管理局（FDA）已授予其实验性双药疗法PIKTOR（联合化疗）快速通道资格，该疗法适用于部分晚期或复发性子宫内膜癌患者，子宫内膜癌是一种起源于子宫内膜的癌症
** FDA的“快速通道”资格旨在加快针对存在未满足医疗需求的严重疾病治疗方案的研发和审查进程
** PIKTOR 由口服药物萨帕尼塞替布（sapanisertib）和塞拉贝利西布（serabelisib）组成，旨在阻断癌症生长信号，目前正在针对先前接受过化疗和免疫治疗后病情恶化的患者进行临床试验
** 该公司预计将于2026年底前获得一项正在进行的中期临床试验的结果
** 截至上一交易日收盘，FTH今年以来累计上涨203.1%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.